Major trial tests new weapon against High-Risk breast cancer return
NCT ID NCT07019363
Summary
This large study is testing whether adding a drug called a CDK4/6 inhibitor to standard hormone therapy helps keep breast cancer from coming back. It involves nearly 2,000 women with a specific, high-risk type of early breast cancer who have already finished their initial targeted therapy. The goal is to see if this extra medication improves long-term survival and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Fudan cancer center
RECRUITINGShanghai, China
Conditions
Explore the condition pages connected to this study.